Ventilator-Associated Pneumonia
Ventilator-associated pneumonia is a hospital-acquired infection. It is mainly caused by germs that enter the lungs through the ventilator tubes of someone who has been placed on a ventilator to assist their breathing.
Quick Answer
What it is
Ventilator-associated pneumonia is a hospital-acquired infection. It is mainly caused by germs that enter the lungs through the ventilator tubes of someone who has been placed on a ventilator to assist their breathing.
Key findings
No graded findings are available yet.
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
ℹ️ Quick Facts
Quick Facts: Ventilator-Associated Pneumonia
- Supplements Studied:0
Evidence-Based Protocol
Supplement stack ranked by research quality
Primary Stack (Tier 1)
Reduce pathogenic colonization in upper airway; may decrease VAP incidence
Supports immune function; deficiency common in ICU patients and associated with worse outcomes
Supporting Stack (Tier 2)
Supports gut barrier function and immune cells; may reduce infections in ICU
Anti-inflammatory effects may help modulate inflammatory response in critical illness
Supports immune function; deficiency common in critically ill patients
Antioxidant; supports immune function in critical illness
Antioxidant; high-dose IV vitamin C studied for sepsis and critical illness
How It Works
Ventilator-associated pneumonia (VAP) is a lung infection that develops in patients on mechanical ventilation, typically occurring more than 48 hours after intubation. It's one of the most common intensive care unit (ICU) infections and significantly increases mortality, ICU stay, and healthcare costs. VAP occurs when bacteria from the mouth, sinuses, or stomach enter the lungs through the breathing tube.
CRITICAL: VAP prevention and treatment is complex medical care managed by ICU physicians. Prevention bundles (head-of-bed elevation, oral care, sedation breaks, DVT/ulcer prophylaxis, daily assessment for extubation) are the primary intervention. Treatment requires appropriate antibiotics based on cultures. These supplements may support immune function and help prevent infections, but they are adjunctive to standard ICU care - not a replacement. All supplement administration in ICU patients must be coordinated with the critical care team and may need to be given through feeding tubes.
* Probiotics have shown the most promise for VAP prevention in ICU patients. They work by reducing colonization of the upper airway with pathogenic bacteria. Multiple meta-analyses show reduced VAP rates.
* Vitamin D deficiency is extremely common (>80%) in ICU patients and is associated with worse outcomes. Supplementation may support immune function and recovery.
* Glutamine supports gut barrier function and immune cells. Results in critically ill patients have been mixed, and it should be avoided in patients with organ failure.
* Omega-3 Fatty Acids have anti-inflammatory effects and have been studied in ARDS and pneumonia with some benefit.
* Zinc and Selenium support immune function and are often depleted in critical illness.
* Vitamin C is an antioxidant that has been studied for sepsis and respiratory failure, with some positive results.
Expected timeline: These are preventive/supportive measures used during the ICU course. VAP treatment with antibiotics typically lasts 7-8 days. Overall ICU outcomes depend on many factors.